Form 4 for DWTX Dogwood Therapeutics, Inc.
Accepted 2021-12-22 00:00:00 ET · period of report 2021-12-21 · accession 0001415889-21-006172 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-22 | 2021-12-21 | DWTX | Duncan Gregory Scott | CEO, Dir | P - Purchase | $5.52 | +5,000 | 25.0K | +25% | +$27.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-21 | P | A | 5,000 | $5.52 | 24,961 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.395 to $5.708, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |